Sunshine Biopharma raises $6M in dilutive public offering with 24M warrants issued

Filed May 19, 2026 · Period ending May 18, 2026 · ~1 min read

Key Changes

• high

  Company sold 12M units at $0.50 each, raising ~$6M gross ($5.5M net after 9% fees). Each unit includes one share plus two warrants exercisable at $0.50, creating 24M warrants that could raise another $12M but would significantly dilute shareholders.

  Item 1.01 verify on EDGAR →
• high

  Series C Warrants are immediately exercisable at $0.50 per share and expire in five years. Full exercise of all 24M warrants would double the current share count from this offering alone.

  Item 1.01 verify on EDGAR →
• medium

  Warrants contain downward anti-dilution protection: if stock price falls below $0.50 after certain corporate actions, exercise price can drop to $0.25 with proportional increase in shares issuable, amplifying dilution risk.

  Item 1.01 verify on EDGAR →